CQN-CA-NAX
14.1.2021 09:03:34 CET | Business Wire | Press release
Please replace the logo in the release dated January 13, 2021 with the accompanying corrected logo.
The release reads:
NAX LAUNCHES AS FIRST PLATFORM TO CREATE CORPORATE ASSET-BACKED PRODUCTS, VENTURES AND SECURITIES
- Company founded by Jeff Schumacher
- Company already valued at over $300m USD
New Asset Exchange (NAX), a company that brings liquidity to corporate assets, has formally launched today after two and a half years in stealth development. It has established a new model for launching corporate asset-backed products, ventures and securities. NAX is founded by serial entrepreneur Jeff Schumacher.
NAX combines the software and the method to identify, build, launch and scale asset-backed products, ventures and securitized assets for institutional trading. NAX has secured $65m USD to date in investment from 12 institutional, family office and corporate investors across North America, Europe and Asia, valuing the company at over $300m USD. It launches with a global team based in North America and Europe.
NAX has developed software for digital, micro and platform services, as well as cloud commerce that can be utilized to rapidly market test fully compliant products, tradable securities and marketplaces. The firm will be announcing a series of milestones in the coming months to match its ambitious growth plans.
NAX is already working with leading global businesses in multiple industries including energy, healthcare and consumer goods to launch corporate asset-backed products, and is supported by operating partners from global leaders in trading, banking and underwriting to deliver the requisite infrastructure.
NAX CEO and founder Jeff Schumacher, previously founded and scaled BCG Digital Ventures, with the company becoming one of the largest foundries in the world, creating more than 100 businesses and growing to over 1,000 employees in less than six years. He also founded Axon Advisory Partners, before selling it to Booz & Co., creating Booz Digital, which was then acquired by PwC. Schumacher was previously a Partner at McKinsey, and also EVP, CMO and CSO at Sports Authority, a Leonard Green Partners portfolio company.
Jeff Schumacher, CEO and Founder, NAX said: “We are building upon a decade of learnings from working with the world's leading financial exchanges and institutions. With NAX, we are bringing financial innovation across sectors to create value in markets that otherwise would not exist.”
Since its inception, NAX has attracted several high-profile business figures to its Board, including Frank Strauß, former Global CEO of Private and Commercial Banking at Deutsche Bank, and Heiner Leisten, Leisten & Cie. Family Office CEO and previously Senior Partner at BCG, among others.
Frank Strauß, Independent Board Member, NAX said: “In today’s world, financial innovation is the bedrock upon which successful ventures are created. Jeff’s vision for NAX is what attracted me to supporting the company in applying financial innovation to corporate assets and ultimately unlocking significant value from those assets.”
Francisco Arcilla, Partner, TNF Investments, which led the latest NAX fundraising round, said: “As an international investment firm that prides itself on being a catalyst for innovation and industry disruption, we were instantly captivated by NAX and its disruptive approach to asset creation and value generation. We were very excited to lead the latest round of funding for NAX, and we are equally enthusiastic about the prospect of the many ventures and further investment opportunities that NAX will create.“
NAX operates from its headquarters in Manhattan Beach, CA for North America and Paris, France for Europe, with further locations in Palo Alto, New York, London, and Frankfurt. In 2021, it will be expanding to Singapore, Tokyo and Sydney.
About NAX
NAX is a platform to create asset-backed products, ventures and securities for the world's leading institutions. We co-lead the commercialization of these initiatives with our partners.
For more information, visit http://www.naxgrp.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210113005031/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom